- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 28.09. | Mirum and Incyte's Atebrioz approved for FOP in US | ||
| 25.09. | Aptar Pharma and Macquarie University partner on drug delivery project | ||
| 25.09. | FDA commissioner nominee affirms MMR vaccine safety despite Trump's claims | ||
| 25.09. | Roche and Earendil forge $1.5bn bispecific discovery deal | ||
| 25.09. | Amberstone and Henlius agree to develop solid-tumour T-cell engagers | ||
| 25.09. | FDA approves Lilly's Onswik for type 2 diabetes in adults | ||
| 24.09. | Eli Lilly outlays $3.35bn for secretive drug discovery pact with China's InnoCare | ||
| 24.09. | Australia starts investigation into OpenAI Medicare breach | ||
| 24.09. | Enveda nabs $311m to progress nature-derived drug pipeline | ||
| 24.09. | Genialis and Inventia to enhance pancreatic cancer treatment testing | ||
| 24.09. | Basecamp Research secures $140m for AI-driven therapies | ||
| 23.09. | European big pharma unites amid 'ringing alarm bells' of continent's dominance | ||
| 23.09. | Boehringer and Envisagenics to develop precision cancer therapies in $1bn deal | ||
| 23.09. | BoomRay and Novartis Pharma sign $900m deal for radioligand therapy | ||
| 23.09. | Boehringer and Envisagenics to develop precision cancer therapies | ||
| 22.09. | Novo targets blockbuster-heavy 2030 but share slump signals unease | ||
| 22.09. | Made Scientific acquires cell therapy facility in Pennsylvania, US | ||
| 22.09. | EC approves Menarini and NewAmsterdam's obicetrapib therapies | ||
| 21.09. | Beijing unveils blueprint for biomedical dominance by 2030 | ||
| 21.09. | Telix to acquire ITM in deal worth up to $2.35bn | ||
| 21.09. | Sandoz and mAbxience agree on emicizumab biosimilar partnership | ||
| 18.09. | FDA approves first gene therapy for Sanfilippo syndrome type A | ||
| 18.09. | Novo targets oral macrocycles with $1.4bn Orbis partnership | ||
| 18.09. | Ona Therapeutics to develop ADC with WuXi's payload-linker platform | ||
| 18.09. | Roche agrees $1bn deal with Dualitas for bispecific antibody research |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.